Table 1 Overview of study characteristics on antimicrobial usage in cancer patients under palliative care
Authors | Study design | Study Duration (m) | Period before death | Number of cancer patients exposed to ATB % | ATB Route | Impact on patients/outcome |
|---|---|---|---|---|---|---|
Mamak et al. [9] | RCS | 12 | NA | 72% | IV, oral | NA |
Al Shaqi et al. [10] | RCS | 14 | Last week of life | 63% | IV, oral, topical | NA |
Azad et al. [11] | RCSÂ | 10Â | NAÂ | 41%Â | NAÂ | NAÂ |
Baek et al. [12] | RCSÂ | 36 | Last 7Â days | 81.4% | NAÂ | NA |
Datta et al. [13] | RCSÂ | 29Â | NAÂ | 82.9% | IV, oral | Longer LOS by 34%Â |
Gao et. al. [14] | RCS | 108 | Last 3 months of life | 26.8% | NA | NA |
Helde-Frankling et al. [15] | RCS | NA | Last two weeks | 49% | IV, oral | Symptomatic relief in 37% (n = 29), mainly in patients with suspected or confirmed sepsis |
Lam PT et al. [5] | RCS | 7 | NA | 117 out of 120 episodes (97.5%) | IV, oral | Symptomatic relief in 39.2% (n = 47) |
Oneschuk D et al. [16] | RCS | 12 | NA | 44% | IV, oral | NA |
OH DY et al. [17] | RCS | 14 | NA | 84.4% | IV, oral | Symptomatic relief in 15.1% (n = 18) |
Thompson AJ et al. [7] | RCS | 48 | NA | 86.9% | IV, oral | NA |
Kwon et al. [6] | RCS | 29 | NA | 96% | IV, oral | No significant impact on fever |
Fombuena et al. [18] | PCS | 14 | NA | 101 out of 127 episodes (79.52%) | IV, oral | Symptomatic relief in 64% (n = 65) |
Mohammed AA et al. [19] | RCS | 15 | NA | 94.2% | IV, oral | Symptomatic relief in 29.2% (n = 71) |
Mirhosseini M. et al. [20] | PCS | 10 | NA | 31 episodes (100%) | IV, oral | Symptomatic relief mainly dysuria and cough |
White PH et al. [21] | PCSÂ | 6 | NAÂ | 77 out of 117 episodes (65.8%)Â | IV, oral | Symptomatic Relief mainly UTIÂ |
Reinbolt RE et al. [22] | PCS | 24 | NA | 633 out of 685 episodes (92.4%) | NA | Symptomatic relief in 79% (n = 265) with UTI, 43% (n = 221) with respiratory infections, 46% (n = 63) in oral cavity infections, and 41%(n = 59) with SSTI |
Chen et al. [23] | RCSÂ | 24Â | NAÂ | 79 out of the 93 febrile episodes (84.9%)Â | IV, oral | Symptomatic relief in 54.4% Positive impact on survival (14.6Â days vs 8.7Â days; p-value: 0.03)Â |
Datta et al. [24] | RCS | 21 | NA | 58% | IV, oral | Increase risk for adverse drug events among those receiving antibiotic (DOT > 1) |
Pandey et al. [25] | RCSÂ | 12Â | Last 1Â week | 59%Â | IV, oral | NAÂ |